Pharmaceutical companies becoming more transparent? GlaxoSmithKline plans to open up much of its drug research in an apparent effort to deflect criticism that important information gathered in clinical trials often does not see the light of day.
Big Pharma’s image problem, fueled by numerous high-profile scandals, may have made doctors so skeptical of the industry that it’s warping their judgment, a new survey suggests, according to Reuters Health.
Pharmas collaborating increasingly with universities. Novartis and the University of Pennsylvania announced a research and licensing agreement that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials.
For more than a decade generic drug makers and big-name pharmaceutical companies have been winning court rulings that allowed them to legally pay a competitor to keep its product off the market for years. Until this month.
European governments are sacrificing the long-term future of science in their countries for the sake of short-term budget cuts, Pfizer chief executive Ian Read told Reuters. Europe is undermining drug innovation by cutting prices, raising barriers to new medicines and freeloading” off others in Asia and the United States who are more willing to pay.